4//SEC Filing
Poukalov Konstantin 4
Accession 0001209191-21-009047
CIK 0001785345other
Filed
Feb 8, 7:00 PM ET
Accepted
Feb 9, 7:56 PM ET
Size
15.4 KB
Accession
0001209191-21-009047
Insider Transaction Report
Form 4
Poukalov Konstantin
Director10% Owner
Transactions
- Purchase
Common Stock
2021-02-09$14.60/sh+34,951$510,285→ 14,869,915 total(indirect: By funds) - Purchase
Common Stock
2021-02-08$12.53/sh+86,671$1,085,988→ 14,768,463 total(indirect: By funds) - Purchase
Common Stock
2021-02-05$11.14/sh+27,453$305,826→ 14,647,181 total(indirect: By funds) - Purchase
Common Stock
2021-02-08$11.38/sh+34,611$393,873→ 14,681,792 total(indirect: By funds) - Purchase
Common Stock
2021-02-08$13.10/sh+1,771$23,200→ 14,770,234 total(indirect: By funds) - Purchase
Common Stock
2021-02-09$13.80/sh+64,730$893,274→ 14,834,964 total(indirect: By funds)
Footnotes (8)
- [F1]The prices reported in Column 4 are weighted average prices. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported on this Form 4.
- [F2]These shares were purchased in multiple transactions at prices ranging from $11.05 to $11.75, inclusive.
- [F3]Securities are held by Perceptive Life Sciences Master Fund, Ltd. ("PLSMF"), Perceptive Xontogeny Venture Fund, LP ("PXVF"), and PX Venture (A), LLC ("PXV"). Perceptive Advisors, LLC ("Perceptive Advisors") serves as the investment manager to PLSMF, PXVF, and PXV. The Reporting Person is a managing director of Perceptive Advisors. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
- [F4]These shares were purchased in multiple transactions at prices ranging from $10.96 to $11.93, inclusive.
- [F5]These shares were purchased in multiple transactions at prices ranging from $11.96 to $12.95, inclusive.
- [F6]These shares were purchased in multiple transactions at prices ranging from $13.09 to $13.10, inclusive.
- [F7]These shares were purchased in multiple transactions at prices ranging from $13.17 to $14.16, inclusive.
- [F8]These shares were purchased in multiple transactions at prices ranging from $14.17 to $15.20, inclusive.
Documents
Issuer
Landos Biopharma, Inc.
CIK 0001785345
Entity typeother
Related Parties
1- filerCIK 0001678736
Filing Metadata
- Form type
- 4
- Filed
- Feb 8, 7:00 PM ET
- Accepted
- Feb 9, 7:56 PM ET
- Size
- 15.4 KB